ReviewCancer journal (Sudbury, Mass.)
Challenges of Pancreatic Cancer.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review.Frontiers in oncology · 2020Pooled it
- The roles of lncRNAs and miRNAs in pancreatic cancer: a focus on cancer development and progression and their roles as potential biomarkers.Frontiers in oncology · 2024Review
- Drug Delivery Strategies for the Treatment of Pancreatic Cancer.Pharmaceutics · 2023Review
- C9orf16 represents the aberrant genetic programs and drives the progression of PDAC.BMC cancer · 2022Article
- Modeling the mechanical stiffness of pancreatic ductal adenocarcinoma.Matrix biology plus · 2022Article
- Imaging Modalities for Early Detection of Pancreatic Cancer: Current State and Future Research Opportunities.Cancers · 2022Review
- ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.Molecular cancer therapeutics · 2021Article
- Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides.Biomolecules · 2020Article
- Contrast-enhanced CT radiomics for predicting lymph node metastasis in pancreatic ductal adenocarcinoma: a pilot study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Article
- Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer.Metabolomics : Official journal of the Metabolomic Society · 2019Article
- Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors.World journal of oncology · 2019Review
- A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer.Cancer management and research · 2019Article
- Serum Derived Exosomes From Pancreatic Cancer Patients Promoted Metastasis: An iTRAQ-Based Proteomic Analysis.OncoTargets and therapy · 2019Article
- Preliminary investigation of the function of hsa_circ_0006215 in pancreatic cancer.Oncology letters · 2018Article
- The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).Cancer biology & therapy · 2018Article
- CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma.Biological research · 2018Article
- Circular RNA circ-LDLRAD3 as a biomarker in diagnosis of pancreatic cancer.World journal of gastroenterology · 2017Article
- Imaging in pancreatic disease.Nature reviews. Gastroenterology & hepatology · 2017Review
- CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The development of novel molecular cancer imaging agents has considerably advanced in recent years. Numerous cancer imaging agents have demonstrated remarkable potential for aiding the diagnosis, staging, and treatment planning at the preclinical stage, which in turn has led to a number of agents being approved for human trials. Pancreatic ductal adenocarcinoma is currently the most deadly common carcinoma with an overall 5-year survival rate of about 6%. As detection technologies progress, the need for molecular imaging tools that will allow the diagnosis at an early stage will be crucial to improving patient outcomes. In this review, we will highlight agents that illuminate various cell populations that comprise the tumor: epithelial, endothelial, and stromal tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.